TD Asset Management Inc Acquires 10,815 Shares of Insulet Corporation $PODD

TD Asset Management Inc raised its holdings in Insulet Corporation (NASDAQ:PODD) by 37.6% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,568 shares of the medical instruments supplier’s stock after buying an additional 10,815 shares during the period. TD Asset Management Inc’s holdings in Insulet were worth $12,216,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. True Wealth Design LLC increased its holdings in shares of Insulet by 288.0% during the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 72 shares during the last quarter. Golden State Wealth Management LLC increased its holdings in shares of Insulet by 202.9% in the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after purchasing an additional 69 shares during the last quarter. Whittier Trust Co. of Nevada Inc. raised its position in shares of Insulet by 48.9% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 43 shares during the period. Quent Capital LLC acquired a new stake in shares of Insulet during the 3rd quarter worth about $49,000. Finally, Osterweis Capital Management Inc. bought a new stake in shares of Insulet during the 2nd quarter worth about $51,000.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Royal Bank Of Canada upped their price target on shares of Insulet from $370.00 to $380.00 and gave the company an “outperform” rating in a research note on Friday, November 21st. Wolfe Research upped their target price on Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Evercore set a $340.00 target price on Insulet in a research note on Thursday, February 19th. Wells Fargo & Company lifted their price target on Insulet from $350.00 to $360.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Finally, Barclays reaffirmed an “underweight” rating and issued a $286.00 price objective on shares of Insulet in a report on Thursday, February 19th. Twenty equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $354.57.

Insider Activity

In other Insulet news, Director Michael R. Minogue acquired 2,030 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was acquired at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the transaction, the director directly owned 17,483 shares in the company, valued at $4,304,839.09. This represents a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.39% of the company’s stock.

Insulet Stock Down 1.9%

Shares of NASDAQ PODD opened at $246.61 on Monday. Insulet Corporation has a 52 week low of $230.05 and a 52 week high of $354.88. The stock’s fifty day moving average is $268.21 and its 200 day moving average is $303.09. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81. The stock has a market capitalization of $17.36 billion, a P/E ratio of 70.46, a PEG ratio of 1.47 and a beta of 1.42.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, beating the consensus estimate of $1.48 by $0.07. The company had revenue of $783.80 million during the quarter, compared to analysts’ expectations of $768.31 million. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.15 EPS. Sell-side analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.